Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Lappuse 1 no 32 rezultātiem
Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND
1. Field of the Invention
This invention relates to analogs of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to neuroprotective GPE analogs, to methods of making them, to pharmaceutical compositions containing them, and to their use in treating neurological
Compositions containing and methods of using N-acyl-1H-aminoindenes
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Throughout this application, various references are identified by authors and full citation. Disclosure of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE
Systems, devices and methods for the treatment of neurological disorders and conditions
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
Systems, devices and methods for the treatment of neurological disorders and conditions
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
Systems, devices and methods for the treatment of neurological disorders and conditions
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This application is also related to the following copending applications: U.S. application Ser. No. 12/898,685, entitled "Extracranial Implantable Devices, Systems and Methods for Treatment of Neuropsychiatric Disorders," filed on even date herewith with U.S. application Ser. No. 12/898,686,
Substituted quinoxaline-2-ones as glutamate receptor antagonists
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The
Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
Method of treating migraine headache without aura
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and compositions for
Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for
Compositions for modulating intracellular inositol trisphosphate concentration
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
This invention relates to modulation of inositol trisphosphate (InsP.sub.3) concentration in neurons.
Within the nervous system, information is conveyed from one neuron to another by electrical signals that are generated by the flux of ions, including calcium ions, across
Tricyclic dicarbonyl derivatives
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This is a 371 application of PCT/EP95/01856, filed May 16, 1995. The present invention is concerned with tricyclic dicarbonyl derivatives of the general formulae ##STR2## wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino,
Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The
Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
1. FIELD OF THE INVENTION
The present invention is directed to the use of peripherally administered erythropoietin and other erythropoietin receptor activity modulators or EPO-activated receptor modulators to positively affect excitable tissue function. This includes the protection of excitable
Modulation of excitable tissue function by peripherally administered erythropoietin
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
1. FIELD OF THE INVENTION
The present invention is directed to the use of peripherally administered erythropoietin and other erythropoietin receptor activity modulators or EPO-activated receptor modulators to positively affect excitable tissue function. This includes the protection of excitable
Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne
- Darbojas 55 valodās
- Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
- Garšaugu atpazīšana pēc attēla
- Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
- Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
- Meklēt ārstniecības augus pēc to iedarbības
- Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem
Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem
